Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 539,600 shares, a drop of 26.7% from the February 13th total of 736,300 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is presently 0.4 days. Currently, 4.4% of the shares of the company are sold short.

Cyclo Therapeutics Trading Down 1.7 %

Shares of CYTH traded down $0.01 during mid-day trading on Tuesday, hitting $0.65. The company’s stock had a trading volume of 64,925 shares, compared to its average volume of 408,680. The firm has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $0.73. The firm has a market capitalization of $21.40 million, a P/E ratio of -0.72 and a beta of -0.57. Cyclo Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.79.

Institutional Investors Weigh In On Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Two Sigma Securities LLC acquired a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.15% of Cyclo Therapeutics as of its most recent SEC filing. 68.55% of the stock is owned by institutional investors and hedge funds.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.